CAR T therapy beyond cancer: the evolution of a living drug
Engineering a patient's own T cells to selectively target and eliminate tumour cells has cured
patients with untreatable haematologic cancers. These results have energized the field to …
patients with untreatable haematologic cancers. These results have energized the field to …
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
E Baulu, C Gardet, N Chuvin, S Depil - Science Advances, 2023 - science.org
T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …
Engineered cellular immunotherapies in cancer and beyond
AV Finck, T Blanchard, CP Roselle, G Golinelli… - Nature medicine, 2022 - nature.com
This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …
modified T cells for refractory leukemia. The widespread commercial approval of genetically …
Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
[HTML][HTML] Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
H Raskov, A Orhan, JP Christensen… - British journal of cancer, 2021 - nature.com
The functions of, and interactions between, the innate and adaptive immune systems are
vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most …
vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most …
[HTML][HTML] CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome
S Arcangeli, C Bove, C Mezzanotte… - The Journal of …, 2022 - Am Soc Clin Investig
Chimeric antigen receptor (CAR) T cell expansion and persistence represent key factors to
achieve complete responses and prevent relapses. These features are typical of early …
achieve complete responses and prevent relapses. These features are typical of early …
[HTML][HTML] CAR-T: what is next?
YJ Chen, B Abila, Y Mostafa Kamel - Cancers, 2023 - mdpi.com
Simple Summary In 2017, two chimeric antigen receptor-T (CAR-T) therapies were
approved by the FDA for advanced/resistant lymphoma and acute lymphoblastic leukemia …
approved by the FDA for advanced/resistant lymphoma and acute lymphoblastic leukemia …
Chimeric antigen receptor T‐cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice
RH Parikh, S Lonial - CA: A Cancer Journal for Clinicians, 2023 - Wiley Online Library
Multiple myeloma (MM) is a hematologic malignancy defined by the clonal proliferation of
transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a …
transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a …
Base editing: advances and therapeutic opportunities
EM Porto, AC Komor, IM Slaymaker… - Nature Reviews Drug …, 2020 - nature.com
Base editing—the introduction of single-nucleotide variants (SNVs) into DNA or RNA in
living cells—is one of the most recent advances in the field of genome editing. As around …
living cells—is one of the most recent advances in the field of genome editing. As around …
Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
P Agarwalla, EA Ogunnaike, S Ahn, KA Froehlich… - Nature …, 2022 - nature.com
Despite their clinical success, chimeric antigen receptor (CAR)-T cell therapies for B cell
malignancies are limited by lengthy, costly and labor-intensive ex vivo manufacturing …
malignancies are limited by lengthy, costly and labor-intensive ex vivo manufacturing …